Refine
Has Fulltext
- yes (18)
Is part of the Bibliography
- yes (18)
Year of publication
Document Type
- Journal article (14)
- Doctoral Thesis (3)
- Review (1)
Language
- English (18) (remove)
Keywords
- rat (18) (remove)
Institute
- Institut für Virologie und Immunbiologie (2)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (2)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (2)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (2)
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (2)
- Neurologische Klinik und Poliklinik (2)
- Pathologisches Institut (2)
- Graduate School of Life Sciences (1)
- Institut für Klinische Neurobiologie (1)
- Institut für Molekulare Infektionsbiologie (1)
EU-Project number / Contract (GA) number
- 602133 (1)
- HEALTH-F2-2009-241778 (1)
This review outlines the most frequently used rodent stroke models and discusses their strengths and shortcomings. Mimicking all aspects of human stroke in one animal model is not feasible because ischemic stroke in humans is a heterogeneous disorder with a complex pathophysiology. The transient or permanent middle cerebral artery occlusion (MCAo) model is one of the models that most closely simulate human ischemic stroke. Furthermore, this model is characterized by reliable and well-reproducible infarcts. Therefore, the MCAo model has been involved in the majority of studies that address pathophysiological processes or neuroprotective agents. Another model uses thromboembolic clots and thus is more convenient for investigating thrombolytic agents and pathophysiological processes after thrombolysis. However, for many reasons, preclinical stroke research has a low translational success rate. One factor might be the choice of stroke model. Whereas the therapeutic responsiveness of permanent focal stroke in humans declines significantly within 3 hours after stroke onset, the therapeutic window in animal models with prompt reperfusion is up to 12 hours, resulting in a much longer action time of the investigated agent. Another major problem of animal stroke models is that studies are mostly conducted in young animals without any comorbidity. These models differ from human stroke, which particularly affects elderly people who have various cerebrovascular risk factors. Choosing the most appropriate stroke model and optimizing the study design of preclinical trials might increase the translational potential of animal stroke models.
Multiple antenatal dexamethasone treatment alters brain vessel differentiation in newborn mouse pups
(2015)
Antenatal steroid treatment decreases morbidity and mortality in premature infants through the maturation of lung tissue, which enables sufficient breathing performance. However, clinical and animal studies have shown that repeated doses of glucocorticoids such as dexamethasone and betamethasone lead to long-term adverse effects on brain development. Therefore, we established a mouse model for antenatal dexamethasone treatment to investigate the effects of dexamethasone on brain vessel differentiation towards the blood-brain barrier (BBB) phenotype, focusing on molecular marker analysis. The major findings were that in total brains on postnatal day (PN) 4 triple antenatal dexamethasone treatment significantly downregulated the tight junction protein claudin-5, the endothelial marker Pecam-1/CD31, the glucocorticoid receptor, the NR1 subunit of the N-methyl-D-aspartate receptor, and Abc transporters (Abcb1a, Abcg2 Abcc4). Less pronounced effects were found after single antenatal dexamethasone treatment and in PN10 samples. Comparisons of total brain samples with isolated brain endothelial cells together with the stainings for Pecam-1/CD31 and claudin-5 led to the assumption that the morphology of brain vessels is affected by antenatal dexamethasone treatment at PN4. On the mRNA level markers for angiogenesis, the sonic hedgehog and the Wnt pathway were downregulated in PN4 samples, suggesting fundamental changes in brain vascularization and/or differentiation. In conclusion, we provided a first comprehensive molecular basis for the adverse effects of multiple antenatal dexamethasone treatment on brain vessel differentiation.
The proteome profiles of the olfactory bulb of juvenile, adult and aged rats - an ontogenetic study
(2015)
Background:
In this study, we searched for proteins that change their expression in the olfactory bulb (oB) of rats during ontogenesis. Up to now, protein expression differences in the developing animal are not fully understood. Our investigation focused on the question whether specific proteins exist which are only expressed during different development stages. This might lead to a better characterization of the microenvironment and to a better determination of factors and candidates that influence the differentiation of neuronal progenitor cells.
Results:
After analyzing the samples by two-dimensional polyacrylamide gel electrophoresis (2DE) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS), it could be shown that the number of expressed proteins differs depending on the developmental stages. Especially members of the functional classes, like proteins of biosynthesis, regulatory proteins and structural proteins, show the highest differential expression in the stages of development analyzed.
Conclusion:
In this study, quantitative changes in the expression of proteins in the oB at different developmental stages (postnatal days (P) 7, 90 and 637) could be observed. Furthermore, the expression of many proteins was found at specific developmental stages. It was possible to identify these proteins which are involved in processes like support of cell migration and differentiation.
Neuropathic pain, caused by a lesion in the somatosensory system, is a severely impairing mostly chronic disease. While its underlying molecular mechanisms are not thoroughly understood, neuroimmune interactions as well as changes in the pain pathway such as sensitization of nociceptors have been implicated. It has been shown that not only are different cell types involved in generation and maintenance of neuropathic pain, like neurons, immune and glial cells, but, also, intact adjacent neurons are relevant to the process. Here, we describe an experimental approach to discriminate damaged from intact adjacent neurons in the same dorsal root ganglion (DRG) using differential fluorescent neuronal labelling and fluorescence-activated cell sorting (FACS). Two fluorescent tracers, Fluoroemerald (FE) and 1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine perchlorate (DiI), were used, whose properties allow us to distinguish between damaged and intact neurons. Subsequent sorting permitted transcriptional analysis of both groups. Results and qPCR validation show a strong regulation in damaged neurons versus contralateral controls as well as a moderate regulation in adjacent neurons. Data for damaged neurons reveal an mRNA expression pattern consistent with established upregulated genes like galanin, which supports our approach. Moreover, novel genes were found strongly regulated such as corticotropinreleasing hormone (CRH), providing novel targets for further research. Differential fluorescent neuronal labelling and sorting allows for a clear distinction between primarily damaged neuropathic neurons and "bystanders," thereby facilitating a more detailed understanding of their respective roles in neuropathic processes in the DRG.
The Proteome Profiles of the Cerebellum of Juvenile, Adult and Aged Rats-An Ontogenetic Study
(2015)
In this study, we searched for proteins that change their expression in the cerebellum (Ce) of rats during ontogenesis. This study focuses on the question of whether specific proteins exist which are differentially expressed with regard to postnatal stages of development. A better characterization of the microenvironment and its development may result from these study findings. A differential two-dimensional polyacrylamide gel electrophoresis (2DE) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) analysis of the samples revealed that the number of proteins of the functional classes differed depending on the developmental stages. Especially members of the functional classes of biosynthesis, regulatory proteins, chaperones and structural proteins show the highest differential expression within the analyzed stages of development. Therefore, members of these functional protein groups seem to be involved in the development and differentiation of the Ce within the analyzed development stages. In this study, changes in the expression of proteins in the Ce at different postnatal developmental stages (postnatal days (P) 7, 90, and 637) could be observed. At the same time, an identification of proteins which are involved in cell migration and differentiation was possible. Especially proteins involved in processes of the biosynthesis and regulation, the dynamic organization of the cytoskeleton as well as chaperones showed a high amount of differentially expressed proteins between the analyzed dates.
We analyzed rest tremor, one of the etiologically most elusive hallmarks of Parkinson disease(PD), in 12 consecutive PD patients during a specific task activating the locus coeruleus (LC) to investigate a putative role of noradrenaline (NA) in tremor generation and suppression. Clinical diagnosis was confirmed in all subjects by reduced dopamine reuptake transporter (DAT) binding values investigated by single photon computed tomography imaging (SPECT) with [\(^{123}\)I] N-\(\omega\)-fluoropropyl-2 \(\beta\)-carbomethoxy-3 \(\beta\)-(4-iodophenyl) tropane (FP-CIT). The intensity of tremor (i.e., the power of Electromyography [EMG] signals), but not its frequency, significantly increased during the task. In six subjects, tremor appeared selectively during the task. In a second part of the study, we retrospectively reviewed SPECT with FP-CIT data and confirmed the lack of correlation between dopaminergic loss and tremor by comparing DAT binding values of 82 PD subjects with bilateral tremor (n = 27), unilateral tremor (n = 22), and no tremor (n = 33). This study suggests a role of the LC in Parkinson tremor.
As a consequence of obstetric complications, neonatal hypoxia has been discussed as an environmental factor in the pathophysiology of schizophrenia. However, the biological consequences of hypoxia are unclear. The neurodevelopmental hypothesis of schizophrenia suggests that the onset of abnormal brain development and neuropathology occurs perinatally, whereas symptoms of the disease appear in early adulthood. In our animal model of chronic neonatal hypoxia, we have detected behavioral alterations resembling those known from schizophrenia. Disturbances in cell proliferation possibly contribute to the pathophysiology of this disease. In the present study, we used postnatal rats to investigate cell proliferation in several brain areas following neonatal hypoxia. Rats were repeatedly exposed to hypoxia (89 % N2, 11 % O2) from postnatal day (PD) 4–8. We then evaluated cell proliferation on PD 13 and 39, respectively. These investigations were performed in the anterior cingulate cortex (ACC), caudate-putamen (CPU), dentate gyrus, and subventricular zone. Rats exposed to hypoxia exhibited increased cell proliferation in the ACC at PD 13, normalizing at PD 39. In other brain regions, no alterations have been detected. Additionally, hypoxia-treated rats showed decreased CPU volume at PD 13. The results of the present study on the one hand support the assumption of chronic hypoxia influencing transient cell proliferation in the ACC, and on the other hand reveal normalization during ageing.
Recent advances in the in vitro characterization of human adult enteric neural progenitor cells have opened new possibilities for cell-based therapies in gastrointestinal motility disorders. However, whether these cells are able to integrate within an in vivo gut environment is still unclear. In this study, we transplanted neural progenitor-containing neurosphere-like bodies (NLBs) in a mouse model of hypoganglionosis and analyzed cellular integration of NLB-derived cell types and functional improvement. NLBs were propagated from postnatal and adult human gut tissues. Cells were characterized by immunohistochemistry, quantitative PCR and subtelomere fluorescence in situ hybridization (FISH). For in vivo evaluation, the plexus of murine colon was damaged by the application of cationic surfactant benzalkonium chloride which was followed by the transplantation of NLBs in a fibrin matrix. After 4 weeks, grafted human cells were visualized by combined in situ hybridization (Alu) and immunohistochemistry (PGP9.5, GFAP, SMA). In addition, we determined nitric oxide synthase (NOS)-positive neurons and measured hypertrophic effects in the ENS and musculature. Contractility of treated guts was assessed in organ bath after electrical field stimulation. NLBs could be reproducibly generated without any signs of chromosomal alterations using subtelomere FISH. NLB-derived cells integrated within the host tissue and showed expected differentiated phenotypes i.e. enteric neurons, glia and smooth muscle-like cells following in vivo transplantation. Our data suggest biological effects of the transplanted NLB cells on tissue contractility, although robust statistical results could not be obtained due to the small sample size. Further, it is unclear, which of the NLB cell types including neural progenitors have direct restoring effects or, alternatively may act via 'bystander' mechanisms in vivo. Our findings provide further evidence that NLB transplantation can be considered as feasible tool to improve ENS function in a variety of gastrointestinal disorders.
Background: Genomic reprogramming is thought to be, at least in part, responsible for the protective effect of brain preconditioning. Unraveling mechanisms of this endogenous neuroprotection, activated by preconditioning, is an important step towards new clinical strategies for treating asphyctic neonates. Therefore, we investigated whole-genome transcriptional changes in the brain of rats which underwent perinatal asphyxia (PA), and rats where PA was preceded by fetal asphyctic preconditioning (FAPA). Offspring were sacrificed 6 h and 96 h after birth, and whole-genome transcription was investigated using the Affymetrix Gene1.0ST chip. Microarray data were analyzed with the Bioconductor Limma package. In addition to univariate analysis, we performed Gene Set Enrichment Analysis (GSEA) in order to derive results with maximum biological relevance.
Results: We observed minimal, 25% or less, overlap of differentially regulated transcripts across different experimental groups which leads us to conclude that the transcriptional phenotype of these groups is largely unique. In both the PA and FAPA group we observe an upregulation of transcripts involved in cellular stress. Contrastingly, transcripts with a function in the cell nucleus were mostly downregulated in PA animals, while we see considerable upregulation in the FAPA group. Furthermore, we observed that histone deacetylases (HDACs) are exclusively regulated in FAPA animals.
Conclusions: This study is the first to investigate whole-genome transcription in the neonatal brain after PA alone, and after perinatal asphyxia preceded by preconditioning (FAPA). We describe several genes/pathways, such as ubiquitination and proteolysis, which were not previously linked to preconditioning-induced neuroprotection. Furthermore, we observed that the majority of upregulated genes in preconditioned animals have a function in the cell nucleus, including several epigenetic players such as HDACs, which suggests that epigenetic mechanisms are likely to play a role in preconditioning-induced neuroprotection.
The mono-6-deoxy-6-azides of 2,6-di-O-methyl-beta-cyclodextrin (DIMEB) and randomly methylated-beta-cyclodextrin (RAMEB) were conjugated to propargylated hydroxyethyl starch (HES) by Cu+-catalysed [2 + 3] cycloaddition. The resulting water soluble polymers showed lower critical solution temperatures (LCST) at 52.5 degrees C (DIMEB-HES) and 84.5 degrees C (RAMEB-HES), respectively. LCST phase separations could be completely avoided by the introduction of a small amount of carboxylate groups at the HES backbone. The methylated CDs conjugated to the HES backbone exhibited significantly lower cytotoxicities than the corresponding monomeric CD derivatives. Since the binding potentials of these CD conjugates were very high, they are promising candidates for new oral dosage forms of anaesthetic actives.
Alzheimer’s disease (AD) is a progressive neurodegenerative disease of the brain. Today AD is the most common form of dementia in elderly people. It is clinically characterized by a progressive loss of memory and later on a decline in higher cognitive functions. The pathological hallmarks of AD, consistently demonstrated in brain tissue of patients, are extracellular amyloid-β (Aβ plaques, intracellular neurofibrillary tangles of tau protein and a profound loss of mainly cholinergic and glutamatergic synapses and ultimatively neurons. Estimates foresee that more than 80 million individuals will be affected by the disease by 2040 due to population aging worldwide underlining the high medical need for this disease. In order to find suitable drugs for the treatment of AD, experimental model systems are utilized to explore potential drug candidates. Such an experimental system is hippocampal long-term potentiation (LTP), which is widely accepted as an in vitro model of cellular processes fundamentally involved in memory formation. The present thesis focuses on the establishment and validation of LTP in rat hippocampal slices to characterize memory enhancing drugs as a potential treatment of AD. First, a multi-slice recording system was set up enabling stable measurements of LTP for up to seven hours from several slices simultaneously (chapter 2). Then, distinct protocols to induce early and late CA1 LTP, resembling short-term and long-term memory, were established. They were validated by addressing the hallmarks accepted for these forms of LTP: protein-synthesis independence and NMDA receptor dependence without contribution of L-VDCCs for early LTP, as opposed to protein-synthesis and NMDA / L-VDCCs dependence for late LTP (chapter 3). As in AD patients a loss of mainly cholinergic and glutamatergic synapses is obvious, these validated forms of LTP were used to study drugs potentially being able to enhance cholinergic and/or glutamatergic neuronal functions. The effects of two drugs exclusively interfering with cholinergic function on LTP were tested: the α4β2 nicotinic acetylcholinergic receptor agonist TC-1827 (chapter 4) and the acetylcholine esterase inhibitor donepezil (chapter 5). Both drugs were found to increase early LTP, but to not affect late LTP. Furthermore, two drugs exclusively interfering with glutamatergic function were analyzed: the metabotropic glutamate 5 receptor postive allosteric modulator ADX-47273 (chapter 3) and the phosphodiesterase (PDE) 9A inhibitor BAY 73-6691 (chapter 5). ADX-47273 increased late LTP, but had no effect on early LTP, whereas BAY 73-6691 showed enhancing effects on both early and late LTP and even transformed early into late LTP. The same effects like for the PDE9A inhibitor were observed for the α7 nicotinic acetylcholinergic receptor partial agonist SSR180711 (chapter 4), which interferes with both, cholinergic and glutamatergic function. Thus, drugs facilitating glutamatergic function or both glutamatergic and cholinergic function seem to be more efficacious in enhancing LTP than drugs facilitating solely cholinergic function. To evaluate whether this finding also proves true for experimental circumstances mimicking decreased cognitive function together with pathophysiology in AD patients, the ability of the drugs to ameliorate LTP impaired by soluble Aβ oligomer was analyzed (chapter 6). Soluble Aβ oligomers, also referred to as amyloid-β derived diffusible ligands (ADDLs), are thought to a putative cause of AD. Here, they were demonstrated to impair early and late LTP to different extents by exclusively targeting NMDA receptors and/or their signaling. These results further contribute to the hypothesis that soluble Aβ oligomers cause synaptic dysfunction which might lead to cognitive decline seen in AD patients. Regarding drug effects, donepezil and TC-1827 slightly restored ADDLs induced impairment of early LTP, but had no effect on late LTP impaired by ADDLs. In contrast, both, SSR180711 and BAY 73-6691 completely rescued early as well as late LTP impaired by ADDLs. ADX-47273 had no restoring effect on ADDLs induced early LTP impairment, but partially restored late LTP impaired by ADDLs. Thus, the earlier finding of the present thesis was confirmed: drugs facilitating glutamatergic function not only seem to be more efficacious in enhancing LTP than drugs facilitating solely cholinergic function, but are also superior in ameliorating soluble Aβ oligomer induced LTP deficits. Therefore, from a preclinical perspective and based on the results of the present thesis, drugs interfering with glutamatergic function seem to have a high therapeutic potential as alternative treatment concerning cognitive deficits. Probably, they represent more efficacious approaches for the symptomatic treatment of AD than current treatments solely facilitating cholinergic function.
To decrease immunogenicity of the rat kidney, grafts were perfused with an anti-MHC class li monoclonal antibody (mAb ). How effectively this procedure blocked dass li-positive cells, which were mainly dendritic in appearance, was checked by immunostaining renal sections after perfusion and comparing them with in vitro stained sections. Optimum conditions were applied for graft pretreatment before transplantation. This procedure prolonged graft survival, though not satisfactorily from the biological point ofview (9.6 ± 0.8 versus 7.7 ± 0.5 days in the control group; P < 0.02). The dendritic cells were not killed but blocked. Several hours after transplantation, the mAb dissociated from these dass li-positive cells. It was also shown that donor cells migrate into the recipient's spieen early after transplantation. The number of these cells was smaller when the transplanted organ was perfused with the mAb. Further studies are suggested to deplete the graft of donor dendritic cells more adequately. They should also combine graft perfusion with antidass II mAb and recipient immunosuppression at reduced doses.
Trichothecenes are mycotoxins which produce Iethai toxicosis in humans and animals, yet no adequate therapeutic regimen has been developed. This study provides evidence that the selective platelet activating factor (PAF) antagonist, BN 52021 (5-15 mg/kg i.v.) can prolong the survival of conscious rats exposed to a highly Iethai T -2 toxicosis. These data also suggest that P AF is an important mediator of this unique toxicosis.
iNKT cells are a population of T cells with unique characteristics. In contrast to most αβ T cells which recognize peptides presented by highly polymorphic MHC molecules, iNKT cells are reactive to glycolipids presented by CD1d, a non-polymorphic MHC-I like molecule. Moreover, whereas MHC-restricted αβ T cells bear highly variable receptors (TCRs) formed after somatic recombination of the V(D)J gene segments, the TCR of iNKT cells is formed by an invariant α chain, which always contains the same gene segments: AV14 and AJ18; and a β chain of limited BV gene usage: BV8S2, BV7 or BV2, in the mouse. This invariant α chain is the reason for which these cells are named “i” and the NK part of their name refers to the expression of receptors typical of natural killer (NK) cells. iNKT cells recognize glycolipids of endogenous and microbial origin. After activation they secrete large amounts of very different cytokines such as IFN-γ and IL-4 and thus influence immune responses and pathological conditions. One of the most potent iNKT cell agonists, recognized by the semi-invariant TCR, is the synthetic glycolipid α-Galactosylceramide (α-Gal). iNKT cells can be visualized using CD1d-multimeric complexes loaded with α-Gal and flow cytometry, since this reagent has enough avidity to stain these cells. Interestingly, mouse iNKT cells can be stained with human α-Gal-loaded CD1d oligomers and human iNKT cells can also be visualized with mouse α-Gal-loaded CD1d oligomers, indicating a high degree of conservation of the recognition of α-Gal presented by CD1d through evolution. Previous studies showed that rats have the genes necessary to build semi-invariant TCRs: They have a CD1d homologue; one or two BV8S2 homologues and interestingly, up to ten AV14 gene segments, which are highly conserved when compared to the mouse genes. Importantly, it has been shown at least for two of these AV14 gene segments that they can produce invariant TCRα chains which, when coexpressed with BV8-containing β chains, react to α-Gal presented by rat CD1d. Furthermore, ex vivo stimulation of primary splenocytes with α-Gal results in the secretion of IL-4 and IFN-γ. Surprisingly, rat semi-invariant TCRs do not recognize α-Gal presented by mouse CD1d and accordingly, mouse α-Gal-loaded CD1d tetramers failed to stain a discrete population of rat iNKT cells. Taking all together, despite that strong evidence suggested that iNKT cells are present in the rat, the direct identification of such population and the analysis of CD1d-restricted immune responses were still pending for this species. Hence the work presented in this doctoral thesis was aimed to identify iNKT cells, to analyze their phenotype and also to study the distribution and function of CD1d in the rat. For these purposes, we produced essential reagents which were still lacking such as rat specific anti-CD1d monoclonal antibodies and rat CD1d oligomers. Importantly, two of three anti-rat CD1d monoclonal antibodies (all of them generated in our laboratory before this thesis was initiated) also recognized mouse CD1d and therefore allowed a direct comparison of CD1d expression between rat and mouse. Whereas CD1d distribution in the hematopoietic system was found to be extremely similar between these two species; in non-lymphatic tissues important differences were observed. Interestingly, CD1d protein was detected at not yet described sites such as the rat exocrine pancreas and rat and mouse Paneth cells. These monoclonal antibodies did not only allowed the analysis of CD1d expression, but also the first demonstration of the function of rat CD1d as an antigen presenting molecule, since cytokine release in response to α-Gal was blocked when they were added to ex vivo cultures of rat primary cells. Staining of primary rat iNKT cells (possible now with the newly generated rat CD1d oligomers) revealed interesting similarities with human iNKT cells. First, we observed that rat iNKT cells are only a minority among all NKR-P1A/B positive T cells. Human iNKT cells constitute also a very small proportion of NKR-P1A (CD161) expressing T cells, whereas in mice inbred strains which express NKR-P1C (NK1.1), most of NKRP1C expressing T cells are iNKT cells. Second, the majority of rat iNKT cells are either CD4 or DN and only a small proportion expresses CD8β. These findings are similar to humans and different to mice which lack CD8+ iNKT cells. Third, analysis of various inbred rat strains demonstrated different iNKT cell frequencies which correlated with cytokine secretion after α-Gal stimulation of primary cells. In comparison to mice, iNKT cell numbers are markedly reduced in rats. In F344 rats, inbred rat strain which released the highest cytokine amounts after α-Gal stimulation, approximately 0.25% and 0.1% of total liver and spleen lymphocytes, respectively, are iNKT cells. In contrast, in LEW rats iNKT cells were practically absent and neither IL-4 nor IFN-γ were detected after stimulation of primary cells with α-Gal. Once more, these frequencies are very close to those observed in humans. Last, as reported for human peripheral blood cells, rat iNKT cells could be easily expanded in vitro by adding α-Gal to cultures of intrahepatic lymphocytes, whereas the expansion of mouse iNKT cells was not possible using the same protocol. The presence of a multimember AV14 gene segment family in the rat is an intriguing characteristic. These AV14 gene segments are extremely homologous except in the CDR2α region. Based on the amino acid sequence of this region they have been divided into two different types: Type I and II. A specific tissue distribution of the different types was proposed in the first study where the presence of several AV14 gene segments was described. We also analyzed the AV14 gene segment usage in F344 and LEW inbred rat strains. In F344 rats we found no preferential usage of either AV14 gene segment type in the spleen and the liver but type II AV14 gene segments appeared more frequently in the thymus. In contrast, LEW rats show a preferential usage of type I AV14 gene segments in all three compartments analyzed: Thymus, spleen and liver. Taken all together, the usage of newly generated reagents allowed to gain novel insights into CD1d expression in the rat and in the mouse and to directly identify rat iNKT cells for the first time. The phenotypic and functional analysis of rat iNKT cells revealed numerous similarities with human iNKT cells. These are of special interest, since rats serve to investigate several pathological conditions including models for autoimmune diseases. The possibility now to analyze iNKT cells and CD1d-restricted T cell responses in the rat might help to understand the pathogenesis of such diseases. In addition, the uncomplicated in vitro expansion and culture of rat iNKT cells should facilitate the analysis of the immunomoldulatory capacities of these cells.
We have demonstrated that the extensive degeneration of motoneurons in the rat facial nucleus after transection of the facial nerve in newborn rats can be prevented by local ciliary neurotrophic factor (CNTF) administration. CNTF differs distinctly from known neurotrophic molecules such as NGF, BDNF and NT-3 in both its molecular characteristics (CNTF is a cytosolic rather than a secretory molecule) and its broad spectrum of biological activities. CNTF is expressed selectively by Schwann cells and astrocytes of the peripheral and central nervous system, respectively, but not by target tissues of the great variety of CNTF -responsive neurons. CNTF mRNA is not detectable by Northern blot or PCR analysis during embryonic development and immediately after birth. However, during the second post-natal week, a more than 30-fold increase in CNTF mRNA and pro tein occurs in the sciatic nerve. Since the period of low CNTF levels in peripheral nerves coincides with that of high vulnerability of motoneurons (i.e. axonallesion results in degeneration of motoneuron cell bodies), insufficient availability of CNTF may be the reason for the rate of lesioninduced cell death of early post-natal motoneurons. Highly enriched embryonic chick motoneurons in culture are supported at survival rates higher than 60% by CNTF, even in single cell cultures, indicating that CNTF acts directly on motoneurons. In contrast to CNTF, the members of the neurotrophin gene family (NGF, BDNF and NT-3) do not support the survival of motoneurons in culture. However, aFGF and bFGF show distinct survival activities which are additive to those of CNTF, resulting in the survival of virtually all motoneurons cultured in the presence of CNTF and bFGF.
Summary: In the present work, two important negative regulators of T cell responses in rats were examined. At the molecular level, rat CTLA-4, a receptor important for deactivating T cell responses, was examined for the expression pattern and in vitro functions. For this purpose, anti-rat CTLA-4 mAbs were generated. Consistent with the studies in mice and humans, rat CTLA-4 was detectable only in CD25+CD4+ regulatory T cells in unstimulated rats, and was upregulated in all activated T cells. Cross-linking rat CTLA-4 led to the deactivation of anti-TCR- and anti-CD28 stimulated (costimulation) T cell responses such as reduction in activation marker expression, proliferation, and cytokine IL-2 production. Although T cells stimulated with the superagonistic anti-CD28 antibody alone without TCR engagement also increased their CTLA-4 expression, a delayed kinetics of CTLA-4 upregulation was found in cells stimulated in this way. The physiological relevance of this finding needs further investigation. At the cellular level, rat CD25+CD4+ regulatory T cells were examined here in detail. Using rat anti-CTLA-4 mAbs, the phenotype of CD25+CD4+ regulatory T cells was investigated. Identical to the mouse and human Treg phenotype, rat CD25+CD4+ T cells constitutively expressed CTLA-4, were predominantly CD45RC low, and expressed high level of CD62L (L-selectin). CD25+CD4+ cells proliferated poorly and were unable to produce IL-2 upon engagement of the TCR and CD28. Furthermore, rat CD25+CD4+ cells produced high amounts of anti-inflammatory cytokine IL-10 upon stimulation. Importantly, freshly isolated CD25+CD4+ T cells from naïve rats exhibited suppressor activities in the in vitro suppressor assays. In vitro, CD25+CD4+ regulatory T cells proliferated vigorously upon superagonistic anti-CD28 stimulation and became very potent suppressor cells. In vivo, a single injection of CD28 superagonist into rats induced transient accumulation and activation of CD25+CD4+ regulatory T cells. These findings suggest firstly that efficient expansion of CD25+CD4+ cells without losing their suppressive effects (even enhance their suppressive activities) can be achieved with the superagonistic anti- CD28 antibody in vitro. Secondly, the induction of disproportional expansion of CD25+CD4+ cells by a single injection of superagonistic anti-CD28 antibody in vivo implies that superagonistic anti-CD28 antibody may be a promising candidate in treating autoimmune diseases by causing a transient increase of activated CD25+CD4+ T cells and thus tipping ongoing autoimmune responses toward selftolerance.